

# Prevalence and risk factors of chronic kidney disease in a populated area with highly moving populations

Running title: Prevalence and risk factors chronic kidney disease

Mohammad Khajedaluae<sup>1</sup>, Sanaz Ahmadi Ghezeldasht<sup>2</sup>, Arman Mosavat<sup>2</sup>,  
Reza Hekmat<sup>3</sup>, Seyed Abdolrahim Rezaee<sup>4,\*</sup>, Tahereh Hassannia<sup>5,\*</sup>

<sup>1</sup> Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>2</sup> Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR), Razavi Khorasan, Mashhad, Iran

<sup>3</sup> Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>4</sup> Immunology Research Center, Inflammation and Inflammatory Diseases Division, Mashhad University of Medical Sciences, Mashhad, Iran

<sup>5</sup> Department of Internal Medicine, Faculty of Medicine, Arash Hospital, Tehran University of Medical Sciences, Tehran, Iran

## Corresponding authors:

\* T. Hassannia

Endocrinology and Metabolism Research Institute  
Tehran University of Medical Sciences, Tehran, Iran

**Tel.:** +98 513 800 2376

**Fax:** +98 513 843 6626

**E-mail:** thassannia@yahoo.co.uk

<https://orcid.org/0000-0001-5815-0667>

\*S.A.R. Rezaee

Immunology Research Center, Inflammation and Inflammatory Diseases Division  
Faculty of Medicine, Mashhad University of Medical Sciences  
Azadi-Square, Medical Campus, **ZIP code:** 9177948564, Mashhad, Iran.

**Tel.:** +98 513 800 2377

**Fax:** +98 513 843 6626

**E-mail:** RezaeeR@mums.ac.ir

<https://orcid.org/0000-0001-6814-5992>

## E-mail address and ORCID of the authors:

**M.K.:** Khajedaluaeem@mums.ac.ir, <https://orcid.org/0000-0001-6275-4455>; **S.A.G.:** snz855951@gmail.com, <https://orcid.org/0000-0002-0975-6133>; **A.M.:** Mosavat@acecr.ac.ir, <https://orcid.org/0000-0002-8408-4664>;

**R.H.:** HekmatR@mums.ac.ir, <https://orcid.org/0000-0002-1108-1307>; **S.A.R.:** RezaeeR@mums.ac.ir, <https://orcid.org/0000-0001-6814-5992>; **T.H.:** thassannia@yahoo.co.uk, <https://orcid.org/0000-0001-5815-0667>.

## Abstract

40 **Background:**Chronic kidney disease (CKD) is a major public health problem worldwide.  
41 Prevalence and associated risk factors of CKD was evaluated in the greater Mashhad, a  
42 highly populated pilgrimage city, in 2018 on 2,976 subjects.

43 **Methods:**This study was carried out in the greater Mashhad, a highly populated pilgrimage  
44 city, in 2018 on 2,976 subjects. For each participant a standard questionnaire, a physical  
45 examination and clinical history were completed. Then biochemical and hematologic tests for  
46 kidney function were performed.

47 **Results:**Obesity was observed more frequently in subjects with CKD, thus BMI was  
48 positively correlated with the prevalence of CKD ( $p<0.001$ ). Moderately reduced GFR was  
49 found in 17.6% and 7.1%, and severely reduce GFR at 0.7% and 0.5%, of males and females,  
50 respectively ( $p<0.001$ ).Drug abuse also showed a strong association with CKD ( $p=0.004$ ), but  
51 smoking did not. Using univariate and multivariate logistic regression of decreased estimated  
52 GFR<60 showed that age (OR=1.06), gender (OR=2.14), diabetes (OR=1.07), hypertension  
53 (OR=1.39) and drug usage (OR=3.29) were risk factors for CKD; BMI was not. The same  
54 statistics showed that only age (OR=1.02), diabetes (OR=2.61) and hypertension (OR=1.16)  
55 were risk factors for albuminuria. The prevalence of hypertension (22.1%) was a risk factor  
56 for CKD, and vice versa. BMI and drug abuse were also risk factors for hypertension, but not  
57 smoking.

58 **Conclusion:**These findings demonstrated that progression of CKD and hypertension in any  
59 population should be considered in the context of changes in human behaviours, etiology,  
60 disease severity, co-occurring diseases, addiction and priority of therapy over prevention.

61 **Keywords:** Cardiovascular risk, chronic kidney disease (CKD), Iran, prevalence, risk factors

## 62 INTRODUCTION

63 Chronic kidney disease (CKD) is becoming a major problem worldwide for health  
64 authorities because of its trend progression and its association with cardiovascular diseases. It  
65 is among the main causes of death that has radically increased in the last 30 years, due to  
66 aging, urbanization, and emerging diabetes, and hypertension, lack of access to adequate  
67 healthcare, herbal medication and incomplete knowledge of its pathogenesis. Nowadays,  
68 researchers have demonstrated that diabetes and hypertension are the two main causes of  
69 kidney disease in the developed world.<sup>1</sup>

70 The most important danger for patients and health authorities are, firstly, the risk of the  
71 disease progressing toward end-stage renal disease (ESRD), a status requiring hemo or  
72 peritoneal dialysis or kidney transplantation, which are costly and debilitating. Secondly,  
73 CKD is a high-risk factor for cardiovascular diseases (CVD).<sup>2-4</sup> By understanding the risk  
74 factors and pathogenesis of CKD in its early stages, it is possible to reduce the occurrence of  
75 CVD and ESRD. Because of the nature of the early stages of CKD, it is not primarily  
76 diagnosed until its progression toward kidney damage has commenced; therefore, more  
77 studies and attention are needed to reduce the development and progression of renal failure  
78 and its adverse consequences. Even serious kidney damage can be delayed through early  
79 diagnosis and CKD therapy.<sup>5,6</sup>

80 According to 2002 KDOQI Guidelines, definition of CKD is a glomerular filtration rate  
81 (GFR) below 60 mL/min/1.73 m<sup>2</sup> for three months or more, irrespective of the cause and with  
82 or without evidence of kidney damage.<sup>7</sup> GFR is assessed by serum creatinine using the  
83 Cockcroft and Gault (CG) and Modification of Diet in Renal Disease (MDRD) equations for  
84 adults.<sup>7,8</sup>

85 In the United States, a national survey, demonstrated that the prevalence of CKD had an  
86 increased trend from 10% in 1988–1994 to 13.1% in 1999–2004.<sup>9</sup> Studies also showed a high

87 prevalence of CKD in Japan's general population, around 18.7%.<sup>10,11</sup>In Asia, Europe and  
88 Australia, similar trends of the high prevalence of CKD have been reported.<sup>12</sup>

89 However, less adjusted and reliable data has been reported from developing countries,  
90 particularly in the Middle East.In Iran, a high prevalence of CKDhas been observed among  
91 people over age 20. In another study, the prevalence of CKD was calculated by MDRD for  
92 the general population of Tehran, and was found to be 18.9% (95% CI 18.2, 20.6).<sup>13</sup>

93 For appropriate management of kidney diseases and prevention or slowing of their  
94 progression, it is pivotal to assessaccurate prevalence rates at particular stages in different  
95 geographic regions. Therefore, in this study,the prevalence and the associated risk factors of  
96 CKD were evaluated in a large, population-based study of Mashhad in Iran. The general  
97 population of Mashhad is 3 million, and, because it is a pilgrimage city, its moving  
98 population is around 20-30 million per year.

99

## 100       **METHODS**

### 101       **Study population and sample size**

102           All participants completed a written informed consent, which was approved by the  
103       Biomedical Ethics Committee of Mashhad University of Medical Sciences. The study was  
104       performed on the general population of the greater Mashhad between May and September  
105       2018.

106           The list of all households under coverage of the city's 20 district health centres (primary  
107       health and treatment services) was used for sampling. A random sample of the households  
108       was taken, stratified by healthcare centre to achieve a distribution similar to the original  
109       population. In each household, one person above the age of 16 was recruited so that the study  
110       included the both genders as well as appropriate percentiles for ages according to the 2011  
111       census in each district. There were 2,976 full participants in this study. Of this sample, 1,045  
112       were male (35.1%) and 1,931 (64.9%) were female.

113           Prior to the beginning of the study a four-day official workshop was coordinated by a  
114       nephrologist, a socio-medical specialist and a biochemist for one physician from each of the  
115       district health centres to discuss the kidney failure signs and symptoms, staging, hypertension  
116       and the priority of precise data collection. Then, medical examinations were performed on  
117       participants and histories and demographic and anthropometric data were taken by these  
118       physicians. Blood pressure was assessed by a mercury sphygmomanometer. Height and  
119       weight were measured using a Seca 217 and 707, respectively. Body mass index (BMI) was  
120       also recorded. The inclusion criteria including; age > 16 year, resident of the district more  
121       than 1 year and filling informed consent. Furthermore, the exclusion criteria were dialysis  
122       treatment, any transplantation, malignancy, HIV infection diagnosis and pregnancy or  
123       pregnancy within the past 6 months. The flowchart 1 shows all the relevant of study  
124       variables.

125 **Sample collection and serological assay**

126 Blood samples were taken between 8-10am after a 10-12 hours overnight fast according to  
127 the protocol of Mashhad's ACECR-Central Medical Lab. Analyses of blood biochemical  
128 agents such as fasting glucose, total cholesterol (TC) and triglyceride (TG), creatinine and  
129 BUN concentrations were carried out at the Central Laboratory of ACECR using a Selectra 2  
130 autoanalyser (Vital Scientific, Netherlands).

131 Urinary factors, including colour, appearance, pH, protein, ketones, Hb,  
132 bilirubin, urobilinogen, blood, glucose, nitrite, bacteria, parasites, crystal, mucus, yeast,  
133 candida, cast, WBC, RBC and Epithelial cell were examined.

134 **Definition of chronic kidney disease**

135 A simplified MDRD equation<sup>14</sup> was used for GFR estimation in this study as follows: GFR  
136 (mL/min/1.73 m<sup>2</sup>) = 186.3 \* (serum creatinine)<sup>-1.154</sup> \* (age)<sup>-0.203</sup> \* (0.742 if female) \*  
137 (1.21 if African American).

138 **Statistical analysis**

139 Data were analysed using SPSS version 16 (SPSS Inc., Chicago, IL, USA). The analyses  
140 were carried out using descriptive statistical indexes including standard deviation, mean and a  
141 confidence interval at 95%.

142 For data analysis, the distributions of the variables were estimated using the Kolmogorov–  
143 Smirnov test. For variables with normal distribution, the parametric test was used, and, for  
144 others, non-parametric tests were used. For qualitative variables, a chi-square test was  
145 used. For non-normal distributed variables, Mann-Whitney and Kruskal Wallis tests were  
146 used. For quantitative variables, *t*-student and one-way ANOVA tests were used. Univariate  
147 and multivariate logistic regression tests were employed to discover risk factors for CKD.  
148 The results were significant if  $p \leq 0.05$ .

149

150 **RESULTS**

151 **Socio-demographic data**

152 Out of the 2,976-full-participant study population, 1,045 of them were male (35.1%) and  
153 1,931 (64.9%) were female. A total of 22.1% participants (20% of women and 52.9% of men)  
154 had hypertension, 8.8% (6.8% women and 12.6% men) had diabetes, and 39% had a history  
155 of chronic diseases. Finally, 4.86% of women and 14.9 % of men had a history of smoking  
156 and 1.8% of participants were drug users(Table 1).

157 As Table 1 shows, the mean age of the population was  $43.52 \pm 14.69$  years, ranging from  
158 16- 60, with an age distribution profound in the 40-59 level and older, in which CKD seems  
159 to be more common.A total of 36% of the subjects were under the age of 40, and 60% were  
160 over the age of 40. This indicates that age is a risk factor for CKD, with CKD being more  
161 frequent in older participants ( $p<0.001$ ). The mean BMI of 25-30 was more frequent in this  
162 study (39.8%),and is in the range of being overweight. Taken together, 22.2% of the subjects  
163 were in the range of obesity, 39.8% were in range of being overweight, and 38.1%fell in the  
164 normal range. Around 62 % of the population fell in the range of being overweight,which are  
165 risk factors for CKD and CVD. BMI has a strong association with the prevalence of CKD  
166 ( $p<0.001$ ), and obesity in this population was more frequent where CKD was more prevalent.  
167 While smoking was not significant factor for CKD occurrence, drug abuse had a strong  
168 association with CKD ( $p=0.004$ ).

169 Furthermore, although the mean albumin in urine in men ( $21.8\pm 2.63$ ) and women  
170 ( $18.4\pm 1.72$ ) was not statistically significant, the mean urine creatinine in men ( $142.82\pm 3.04$ )  
171 and women ( $125.8\pm 2.14$ ) was significant ( $p<0.001$ ). The mean concentration of serum  
172 creatinine in men was 1.23 mg/dL and in women was 1.04 mg/dL.This difference was  
173 significant ( $p<0.001$ ). The mean estimated GFR,  $71.29\text{mL}/\text{min}/1.73\text{m}^2$  in men was 71.29 and

174 in women was 84.84, a statistically significant difference ( $p < 0.001$ ). Taken together, the  
175 indices for renal function in females was generally better than in men (Table 1).

#### 176 **Kidney function and albuminuria**

177 According to the GFR, mL/min/1.73 m<sup>2</sup>, about 12.1% of men and 40.3% of women had a  
178 GFR over 90 and in range of normal; 69% of men and 52% women had a GFR 60-89, in  
179 range of mildly reduced kidney function. Moreover, around 17.6% of men and 7.1% of  
180 women had moderately reduced GFR, and 0.7% of men and 0.5% of women had severely  
181 reduced GFR. The differences between men and women in these categories were  
182 significant ( $p < 0.001$ ). Table 2 demonstrates kidney function according to GFR, mL/min/1.73  
183 m<sup>2</sup> (A) and albuminuria (B).

#### 184 **Prevalence of chronic kidney disease**

185 In men, 10.8%, 68.3%, 20.2%, 0.5%, 0.2% was in CKD stages of 1-5, respectively.  
186 However, in women, there were radically different distributions of CKD stages: 44.4%,  
187 51.1%, 4.2%, 0.1% and 0.2% in stages 1-5, respectively ( $p < 0.001$ ) (Table 3).

#### 188 **Main risk factors of CKD manifestation**

189 Using univariate and multivariate logistic regression of decreased estimated GFR < 60  
190 mL/min/1.73 m<sup>2</sup> showed that age (OR=1.06), gender (OR=2.14), diabetes (OR=1.07),  
191 hypertension (OR=1.39) and drug use (OR=3.29) were the primary risk factors for CKD in  
192 this population, and that BMI was not (Table 4-A). However, univariate and multivariate  
193 logistic regression results showed that only age (OR=1.02), diabetes (OR=2.61), and  
194 hypertension (OR=1.16) were risk factors for albuminuria (4B).

195 The distributions of estimated GFR and albuminuria are shown in Fig. 1. It was expected  
196 that there would be a normal distribution of GFR and albumin-to-creatinine (Al/Cr) ratio, as  
197 GFR had a symmetric normal distribution. However, the Al/Cr ratio was not normal, and most  
198 of the subjects (40%) had ratio indices between 5 and 24.99. The prevalence of subjects with

199 GFR below 60 mL/min/1.73 m<sup>2</sup> was around 12.8%, but most of the subjects (72.6%) had  
200 GFR between 60-100 mL/min/1.73 m<sup>2</sup>.

201 The prevalence of CKD increased with age, as expected. As Fig.2 shows, the under curve  
202 area demonstrates the percentage of CKD stages for each age category; for example, the  
203 subjects in stage 3 increased from 1.30% in age groups <30 to 3%, 10%, 23.3% and 39.8% in  
204 age groups of 30-39, 60-69 and >70, respectively. There were no cases of stages of 4 and 5 in  
205 age groups <30, 30-39, 40-59 and 60-69. However, stage 4 and 5 cases were found in 0.30%  
206 and 0.40% of participants in age groups 40-59 and in 1% for the age group >70 years. These  
207 trends in increasing in CKD stages according to age were expected, as instances of a GFR  
208 below 90 mL/min/1.73 m<sup>2</sup> increases with age.

209

210

211 **DISCUSSION**

212 In this study, the prevalence of CKD was investigated in Mashhad, a city with a  
213 population of more than 3 million inhabitants and a moving population of around 20 to 30  
214 million people per year. Mashhad is the second-most-populated city in Iran and is the capital  
215 of Razavi Khorasan province. It has a highly-mixed population of Arab, Turkic and  
216 Mongolian and Afghan tribes. This diversity makes it a city of interest for an investigation  
217 into the main risk factors for CKD.

218 Although smoking was not a risk factor, addiction was a strong risk factor (OR=3.25) for  
219 CKD occurrence. There are two reasons for this. Firstly, opium is the main drug that is  
220 popular in Iranian drug culture, and it can cause kidney damage.<sup>15</sup> Our findings in the lab  
221 show that most of commercial opium is contaminated by heavy metals, particularly lead  
222 which can intensify tissue injury.<sup>16</sup> Secondly, many young drug users use amphetamine  
223 derivatives. These drugs and their contaminations are more likely the main reasons for renal  
224 malfunction in drug users.

225 The progressive aging of the subjects and the epidemics of obesity and diabetes in many  
226 countries complicates to the worldwide burden of CKD.<sup>17</sup> A cohort study in Iran between  
227 1997 and 2000 demonstrated with the MDRD equation that the overall prevalence of CKD  
228 was 18.9% and age-adjusted prevalence was 14.9%.<sup>13</sup> In our study, the prevalence of CKD in  
229 Mashhad was 10% strongly lower than other studies in Iran. A precise scientific evaluation of  
230 some of those studies clarifies that their methodology were not adjusted for CKD and at the  
231 planning stage not intended to measure its prevalence, thus may have had biases.

232 This study demonstrated that the age distribution is profound in the age group 40-59 and  
233 older, in which CKD seems to be more common; 36% of the subjects were between 40 and  
234 60. This was expected as CKD is more frequent in older subjects ( $p < 0.001$ ). CKD affects 10%  
235 to 15% of adults in the United States, Europe, and Asia<sup>9,18</sup>, and prevalence increases with

236 age.<sup>9</sup>This implies that low eGFR reflects only aging, and some studies suggest that existing  
237 CKD guidelines should be used in older population or subjects.<sup>19-22</sup>

238 In the present study, hypertension in uni- and multi-variant regression was not a risk factor  
239 in our region as a middle class population. CKD is a multi-factor disease with wide variation  
240 in risks the world. Growing evidence demonstrated that even diabetes and hypertension in  
241 more developed countries associated with CKD, in low and middle income countries apart  
242 from race and age, other risk factors such as herbal medications, life style, diet, non-  
243 communicable diseases, genetic factors, and water scarcity factors had strong association  
244 with kidney failure.<sup>23,24</sup>

245 On the other hand, in the literature there are studies in favour or opposition of association  
246 between hypertension and renal failure, in Italy compared with the USA, diabetes and  
247 hypertension largely fail to explain the lower prevalence of CKD. Furthermore, in a review,  
248 by Luca De Nicola, these controversial results have been discussed, it is stated that “four  
249 countries with lower CKD prevalence (6.8% overall) had a higher (rather than lower)  
250 prevalence of hypertension and then the four countries showing higher CKD prevalence  
251 (12.2% overall)”.<sup>23</sup>

252 Therefore, in our region with emphasis on the heterogeneity of the residents, hypertension  
253 did not meet significant association with CKD. Taken together, by deep observation on renal  
254 failure and staging, our understanding of hypertension and CKD as direct cause radically  
255 changed, it is more likely that two factors being possibly attributable to the amelioration of  
256 kidney damages including, endothelial dysfunction and inflammation.

257 The mean BMI of 25-30 (overweight) was more frequent in this study (39.8%), which,  
258 using conventional statistical analysis, shows that obesity is a risk factor for CKD ( $p<0.001$ ).  
259 However, univariate and multivariate logistic regression showed that BMI was not a risk  
260 factor either for decreased GFR or for albuminuria. One study demonstrated that, as BMI

261 decreased, the incidence of ESRD also declined. However, this does not suggest that low  
262 BMI implies a low risk of ESRD.<sup>25</sup> In fact, Ramirez *et al.* demonstrated that patients with very  
263 low BMIs had an increased risk of proteinuria.<sup>11</sup>

264 Bosmaet *al.* suggested that the effects of BMI on renal function are not only limited to  
265 manifestations of obesity but also other factors, such as diabetes.<sup>26</sup>

266 The controversial impact of BMI on survival in general and renal failure in particular has  
267 been comprehensively reviewed by elsewhere.<sup>27,28</sup> Briefly, in renal failure, body mass and  
268 particularly, BMI may be confused by hydration disorders, different stages of CKD and in the  
269 elderly. Therefore, to resolve the controversy around BMI in survival and renal failure, it is  
270 pivotal to take into account muscle mass, fat or adipose tissue mass, fat distribution and lean  
271 body mass rather than BMI. The molecular studies showed that, although, leptin and  
272 adiponectin secretion from adipose tissue require for energy and glucose homeostasis, the  
273 production of adipokines (TNF- $\alpha$ , and IL-6) promote inflammation which might be  
274 complicated in diseases manifestation. Therefore instead of BMI and obesity, the direct  
275 mechanisms of adipose tissue on renal failure and survival must take into account.

276 Multiple studies in Iran demonstrated that female gender was the strongest risk factor for  
277 CKD.<sup>13,29</sup> However, in this study, as table 1 shows, there were associations between GFR and  
278 gender, serum creatinine and gender ( $p < 0.001$ ). Around 17.6% of males and 7.1% of females  
279 had moderately reduced GFR, and 0.7% of males and 0.5% of females had severely reduced  
280 GFR. Therefore, the indices for renal function in females are generally better than in males.

281 In the present study, 10.8%, 68.3%, 20.2%, 0.5% and 0.2% of males were in CKD stages  
282 1-5, respectively. However, in females, there was a radically different distribution of CKD  
283 stages: 44.4%, 51.1%, 4.2%, 0.1% and 0.2% for stages 1-5, respectively ( $p < 0.001$ ). Although  
284 GFR has a symmetric normal distribution (Fig.1), the Al/Cr ratio does not. Most of the  
285 subjects (40%) had Al/Cr ratios between ~ 5 and 24.99, and 72.6% of subjects were fallen

286 between 60 and 100 mL/min/1.73 m<sup>2</sup> for the GFR index. However, as previously  
287 suggested, differential errors in GFR estimation cannot be denied.<sup>9</sup>

288 The prevalence of CKD increases with age, as expected (Fig. 2). For example, the subjects  
289 in stage 3 increased from 1.30% in the age group <30 to 3%, 10%, 23.3% and 39.8% in age  
290 groups 30-39, 60-69 and >70 years, respectively. There were not any case of stages of 4 and 5  
291 in age groups <30, 30-39, 40-59 and 60-69. However, there was a 0.30% occurrence of stage  
292 4 and a 0.40% occurrence of stage 5 in the age group 40-59 and was a 1% occurrence for the  
293 age groups >70 years. These trends in increasing CKD stages in accordance with age were  
294 expected, as GFRs below 90 mL/min/1.73 m<sup>2</sup> decreases with age.

295 Finally, there are limitations in this study; we did not consider deeply the socioeconomic  
296 condition of household. Using MDRD method, we did not measure serum creatinine and  
297 urine albumin in an interval time in negative subjects to reach lowest bias as finding curable  
298 acute kidney can effect on our CKD staging. The dietary history and herbal medications  
299 which may impact on kidney function did not record.

300 In conclusion, these findings show that interpretation of the high prevalence of CKD in  
301 this population should be considered in the context of the changes in human behaviours,  
302 addiction, and disease therapy vs. prevention, etiology, disease severity and co-occurring  
303 diseases.

304 Albuminuria is the strongest risk factor for CKD progression and increased risk of  
305 cardiovascular diseases.<sup>30</sup> Reduced GFR in chronic kidney disease, particularly in stages 3  
306 and 4, is associated with complications in the cardiovascular system and high costs of  
307 treatment in end-stage renal disease. Taken together, more initiatives are needed to reduce the  
308 incidence of CKD, such as greater responsibility among health authorities, an emphasis on  
309 therapy instead of prevention, and collecting more reliable data to predict complications of  
310 reduced GFR, kidney disease progression and cardiovascular manifestations. Therefore, it

311 is necessary to establish a world scientific program for reducing CKD as an important cause  
312 of disease complications and costs for governments. For example, it is pivotal to establish  
313 diagnostic guidelines for early stages of CKD that very likely to prevent progression toward  
314 (ESRD) and cardiovascular diseases.

315 In our country, attention to CKD and its preventive programs is very low, particularly in  
316 the early stages of CKD, but the cost of treatment, particularly for ESRD, is very high.  
317 Therefore, lack of planning for CKD prevention and reliance on treatment is expected to  
318 progress ESRD even more dramatically as the population continues to age.

### 319 **Abbreviations**

320 **AI/Cr**, albumin-to-creatinine ratio; **BMI**, Body mass index; **CG**, Cockcroft and  
321 Gault; **CKD**, Chronic kidney disease; **CKD-EPI**, Chronic Kidney Disease Epidemiology  
322 Collaboration; **CVD**, cardiovascular disease; **ESRD**, end-stage renal disease; **GFR**,  
323 glomerular filtration rate; **KDOQI**, Kidney Disease Outcome Quality Initiative; **MDRD**,  
324 Modification of Diet in Renal Disease; **RBC**, Red blood cells; **TC**, total cholesterol; **TG**,  
325 triglyceride; **WBC**, White blood cells.

### 326 **ACKNOWLEDGEMENTS**

327 The authors have great thank to Mrs Shohreh Yaghootkar who sorted all questionnaires,  
328 clinical history, laboratory tests and entered the data to the SPSS software. We greatly  
329 appreciate to Mrs Samaneh Amiri was our great colleague in arrangement of sample collections  
330 from 20 Health centres and running laboratory tests in the ACECR-Central Medical Lab. This  
331 study was financially supported by the Vice-Chancellor for Research and Technology,  
332 Mashhad University of Medical Sciences, Mashhad, Iran, under Grant [**MUMS 87099**].

333

### 334 **CONFLICT OF INTEREST**

335 The authors declare that they have no conflict of interest.

## 336 **ETHICS APPROVAL AND INFORM CONSENT**

337 All procedures performed in studies involving human participants were in accordance with  
338 the ethical standards of the institutional and/or national research committee and with the 1964  
339 Helsinki declaration and its later amendments or comparable ethical standards. This study  
340 was reviewed, approved and supervised by the Biomedical Research Ethics Committee of  
341 Mashhad University of Medical Sciences [IR.MUMS.REC.87099]. Informed consent was  
342 obtained from all individual participants included in the study.

## 343 **DATA AND MATERIALS AVAILABILITY STATEMENT**

344 The data that support the findings of this study are included in this manuscript and  
345 available from the corresponding author (S.A.R. Rezaee) upon reasonable request.

## 346 **AUTHOR'S CONTRIBUTIONS**

347 S.A.R. Rezaee and T. Hassannia designed the study and arranged the laboratory tests. M.  
348 Khajedaluae did the statistical designs and supervised the data collections. S.A.R. Rezaee and  
349 S. Ahmadi Ghezeldasht supervised laboratory tests supervision and quality controls. T.  
350 Hassannia and M. Khajahdaluae run the workshops for physicians and questioners. M.  
351 Khajedaluae and S. Ahmadi Ghezeldasht performed the statistical analysis of the data. R.  
352 Hekmat as nephrologist was one of research advisors, S. Ahmadi Ghezeldasht and A.  
353 Mosavat wrote the draft. S.A.R. Rezaee, A. Mosavat and T. Hassannia revised and completed  
354 the manuscript.

355

356       **REFERENCES**

- 357       1.       Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors  
358           for chronic kidney disease: a prospective study of 23,534 men and women in  
359           Washington County, Maryland. *J Am Soc Nephrol* 2003;14(11):2934-41.
- 360       2.       Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of  
361           premature cardiovascular disease. *J Intern Med* 2010;268(5):456-67.
- 362       3.       Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann  
363           JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms,  
364           and prevention. *Lancet* 2013;382(9889):339-52.
- 365       4.       Levey A, Atkins R, Coresh J, Cohen E, Collins A, Eckardt K-U, et al. Chronic kidney  
366           disease as a global public health problem: approaches and initiatives—a position  
367           statement from Kidney Disease Improving Global Outcomes. *Kidney international*  
368           2007;72(3):247-59.
- 369       5.       Locatelli F, Vecchio LD, Pozzoni P. The importance of early detection of chronic  
370           kidney disease. *Nephrol Dial Transplant* 2002;17 Suppl 11:2-7.
- 371       6.       Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of  
372           chronic renal diseases. *Lancet* 2001;357(9268):1601-8.
- 373       7.       Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney  
374           Foundation practice guidelines for chronic kidney disease: evaluation, classification,  
375           and stratification. *Ann Intern Med* 2003;139(2):137-47.
- 376       8.       Verhave JC, Balje-Volkers CP, Hillege HL, de Zeeuw D, de Jong PE. The reliability  
377           of different formulae to predict creatinine clearance. *J Intern Med* 2003;253(5):563-  
378           73.
- 379       9.       Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of  
380           chronic kidney disease in the United States. *JAMA* 2007;298(17):2038-47.

- 381 10. Imai E, Horio M, Iseki K, Yamagata K, Watanabe T, Hara S, et al. Prevalence of  
382 chronic kidney disease (CKD) in the Japanese general population predicted by the  
383 MDRD equation modified by a Japanese coefficient. *Clin Exp Nephrol*  
384 2007;11(2):156-63.
- 385 11. Ramirez SP, McClellan W, Port FK, Hsu SI. Risk factors for proteinuria in a large,  
386 multiracial, southeast Asian population. *J Am Soc Nephrol* 2002;13(7):1907-17.
- 387 12. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ, et al.  
388 Prevalence of kidney damage in Australian adults: The AusDiab kidney study. *J Am*  
389 *Soc Nephrol* 2003;14(7 Suppl 2):S131-8.
- 390 13. Hosseini F, Kasraei F, Nassiri AA, Azizi F. High prevalence of chronic kidney  
391 disease in Iran: a large population-based study. *BMC Public Health* 2009;9(1):44.
- 392 14. Levey A, Greene T, Kusek J, Beck G. A simplified equation to predict glomerular  
393 filtration rate from serum creatinine [Abstract]: *J Am Soc. Nephrol* 2000;11.
- 394 15. Sepanlou SG, Barahimi H, Najafi I, Kamangar F, Poustchi H, Shakeri R, et al.  
395 Prevalence and determinants of chronic kidney disease in northeast of Iran: Results of  
396 the Golestan cohort study. *PLoS One* 2017;12(5):e0176540.
- 397 16. Muntner P, He J, Vupputuri S, Coresh J, Batuman V. Blood lead and chronic kidney  
398 disease in the general United States population: results from NHANES III. *Kidney Int*  
399 2003;63(3):1044-50.
- 400 17. Martín-Cleary C, Ortiz A. CKD hotspots around the world: where, why and what the  
401 lessons are. A CKJ review series. *Clinical kidney journal* 2014;7(6):519-23.
- 402 18. Zhang L, Zhang P, Wang F, Zuo L, Zhou Y, Shi Y, et al. Prevalence and factors  
403 associated with CKD: a population study from Beijing. *Am J Kidney Dis*  
404 2008;51(3):373-84.

- 405 19. Conway B, Webster A, Ramsay G, Morgan N, Neary J, Whitworth C, et al. Predicting  
406 mortality and uptake of renal replacement therapy in patients with stage 4 chronic  
407 kidney disease. *Nephrol Dial Transplant* 2009;24(6):1930-7.
- 408 20. Poggio ED, Rule AD. A critical evaluation of chronic kidney disease—should  
409 isolated reduced estimated glomerular filtration rate be considered a ‘disease’? :  
410 Oxford University Press; 2008.
- 411 21. Van Pottelbergh G, Bartholomeeusen S, Buntinx F, Degryse J. The evolution of renal  
412 function and the incidence of end-stage renal disease in patients aged  $\geq$  50 years.  
413 *Nephrology Dialysis Transplantation* 2011;27(6):2297-303.
- 414 22. Winearls CG, Glassock RJ. Classification of chronic kidney disease in the elderly:  
415 pitfalls and errors. *Nephron Clin Pract* 2011;119 Suppl 1(Suppl. 1):c2-4.
- 416 23. De Nicola L, Zoccali C. Chronic kidney disease prevalence in the general population:  
417 heterogeneity and concerns. *Nephrol Dial Transplant* 2016;31(3):331-5.
- 418 24. Stanifer JW, Maro V, Egger J, Karia F, Thielman N, Turner EL, et al. The  
419 epidemiology of chronic kidney disease in Northern Tanzania: a population-based  
420 survey. *PLoS One* 2015;10(4):e0124506.
- 421 25. Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S. Body mass index and the  
422 risk of development of end-stage renal disease in a screened cohort. *Kidney Int*  
423 2004;65(5):1870-6.
- 424 26. Bosma RJ, Homan JJ, Heide V, Oosterop EJ, de Jong PE, Navis G. Body mass index  
425 is associated with altered renal hemodynamics in non-obese healthy subjects. *Kidney*  
426 *international* 2004;65(1):259-65.
- 427 27. Cuppari L. Diagnosis of obesity in chronic kidney disease: BMI or body fat? *Nephrol*  
428 *Dial Transplant* 2013;28 Suppl 4:iv119-21.

- 429           28.    Mafra D, Guebre-Egziabher F, Fouque D. Body mass index, muscle and fat in chronic  
430           kidney disease: questions about survival. *Nephrol Dial Transplant* 2008;23(8):2461-  
431           6.
- 432           29.    Malekmakan L, Khajehdehi P, Pakfetrat M, Malekmakan A, Mahdaviazad H,  
433           Roozbeh J. Prevalence of chronic kidney disease and its related risk factors in elderly  
434           of southern iran: a population-based study. *ISRN Nephrol* 2013;2013:427230.
- 435           30.    Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up  
436           and outcomes among a population with chronic kidney disease in a large managed  
437           care organization. *Archives of internal medicine* 2004;164(6):659-63.

438

439

440 **FIGURE LEGENDS**

441 **FIGURE 1.** The distribution of estimated **A**, GFR and **B**, albuminuria.

442

443 **FIGURE 2.** Prevalence of Chronic Kidney Disease (CKD) Stages by Age Group. The under  
444 curve area demonstrates the percentage of CKD stages for each age categories.

445

446

**TABLE 1. The characteristics of study population according to the gender.**

Character	Male (n=1044)	Female (n=1930)	Total (n=2974)	p-value
Age(y)	46.1(15.75)	42.12(13.89)	43.52(14.69)	<0.001
<b>Age group</b>				
<30	19.41	24.8	22.9	
30-39	16.5	18.4	17.8	
40-59	43.4	44.9	44.4	<0.001
60-69	11.5	8.8	9.7	
>70	9.1	3.2	5.3	
Body mass index <sup>a</sup>	25.72(4.15)	27.15(5.03)	26.65(4.79)	<0.001
<b>Body mass index (classification %)</b>				
<18	3.8	3.3	3.4	
18-25	39.8	31.9	34.7	
25-30	42.5	38.3	39.8	<0.001
30-35	11.4	19.8	16.9	
>35	2.5	6.7	5.3	
Smoking%	14.92	4.86	8.40	<0.001
Drug abusing%	3.8	0.7	1.8	<0.001
Diabetes, diagnosed%	11.7	6.5	8.3	<0.001
Hypertension, diagnosed%	25.9	20.0	22.1	<0.001
History of chronic disease%	39.2	38.9	39	0.89
Urine albumin, mg/dL	21.8(2.63)* 5.3(1-12)**	18.4(1.72) 5.7(1-12)	19.59(1.45) 5.47(1-12)	0.25
Urine creatinine, mg/dL	142.82(3.04) 130(90.35-183.65)	125.8(2.14) 115(73-164.5)	131.7(1.76) 122(77.8-172.7)	<0.001
Serum creatinine, mg/dL	1.23(0.009) 1.2(1.1-1.3)	1.04(0.007) 1(0.9-1.1)	1.11(0.006) 1.11(1-1.2)	<0.001
Estimated GFR, 71.29mL/min/1.73m <sup>2</sup>	71.29(0.62) 69.58(61.6-80.4)	84.84(0.53) 84.26(84.2-96.8)	80.15(0.43) 78.8(66.6-92.2)	<0.001
<sup>a</sup> Calculated as weight in kilograms divided by height in meters squared.				
*mean (SD)				
** median (25-75 percentiles)				

447

448

449

**TABLE 2. Prevalence of A, Kidney Function and B, Albuminuria categories in the study population.**

<b>Kidney function (GFR), mL/min/1.73 m<sup>2</sup></b>	<b>Male (n=1044)</b>	<b>Female (n=1930)</b>	<b>Total (n=2974)</b>	<b>p-value</b>
<b>Normal (≥90)</b>	12.1	40.3	30.6	
<b>Mildly reduced (60-89)</b>	69.5	52	58	<0.001
<b>Moderately reduced (30-59)</b>	17.6	7.1	10.7	
<b>Severely reduced (&lt;30)</b>	0.7	0.5	0.6	
<b>Albuminuria (ACR), mg/gb</b>				
<b>Overall</b>	12.6	11.4	11.8	0.49
<b>Normal</b>				
<b>GFR ≥90</b>	8.8	11.9	11.6	0.48
<b>mL/min/1.73 m<sup>2</sup></b>				
<b>GFR 60-89</b>	12.6	10.3	11.3	0.29
<b>mL/min/1.73 m<sup>2</sup></b>				
<b>GFR 30-59</b>	14.8	16.1	15.1	0.85
<b>mL/min/1.73 m<sup>2</sup></b>				
<b>GFR &lt;30</b>	0.0	0.0	0.0	
<b>mL/min/1.73 m<sup>2</sup></b>				

450

451

**TABLE 3.**Prevalence of Chronic Kidney Disease (CKD) according to the stages.

<b>CKDStage</b>	<b>Male (n=1044)</b>	<b>Female (n=1930)</b>	<b>Total(n=2974)</b>	<b>p-value</b>
<b>1</b>	10.8	44.4	32.9	<0.001
<b>2</b>	68.3	51.1	57	
<b>3</b>	20.2	4.2	9.7	
<b>4</b>	0.5	0.1	0.2	
<b>5</b>	0.2	0.2	0.2	
<b>Total</b>	100	100	100	

452

453

454

<b>TABLE 4. A) Logistic Regression of Decreased Estimated Glomerular Filtration Rate (GFR)&lt;60 mL/min/1.73 m<sup>2</sup> in</b>							
	B	SE	P	Univariate		Multivariate	
				OR	95%CI	OR	95%CI
Adjusted for age	0.069	0.005	<0.001	1.07	1.06-1.08	1.06	1.05-1.07
Gender (male)	1.015	0.135	<0.001	2.76	2.12-3.59	2.14	1.59-2.89
Diagnosed diabetes	0.674	0.201	0.001	1.96	1.32-2.91	1.07	0.69-1.66
Diagnosed hypertension	0.982	0.142	<0.001	2.67	2.02-3.52	1.39	1.04-1.92
Body mass index	0.015	0.014	0.29	1.01	0.97-1.04	0.99	0.96-1.02
<b>B) Logistic Regression of Albuminuria</b>							
	B	SE	P	Univariate		multivariate	
				OR	95%CI	OR	95%CI
Adjusted for age	0.021	0.006	<0.001	1.02	1.01-1.03	1.02	1.002-1.03
Gender (male)	0.112	0.167	0.5	1.11	0.81-1.55	0.86	0.59-1.25
Diagnosed diabetes	1.053	0.226	<0.001	2.86	1.84-4.46	2.61	1.62-4.22
Diagnosed hypertension	0.563	0.183	0.002	1.75	1.22-2.51	1.16	0.76-1.78
Body mass index	0.015	0.017	0.37	1.01	0.98-1.05	0.99	0.96-1.03
Abbreviations: CI, confidence interval; OR, odds ratio.							

455

456



